



SmartPA Criteria Proposal

Drug/Drug Class:	Actinic Keratosis Agents, Topical PDL Edit
First Implementation Date:	July 13, 2017
Revised Date:	July 1, 2021
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Actinic Keratosis (AK) is a premalignant condition of the skin that manifests as small, thick, scaly patches of the skin. It is seen mostly in sun-exposed areas of the skin and should be treated due to its potential to progress into a squamous cell carcinoma. A United States-based actinic keratosis guideline is not available, but the 2015 guideline from the International League of Dermatological Societies provides recommendations for the treatment options of actinic keratosis. The guideline mentions that topical diclofenac, fluorouracil, imiquimod, or ingenol mebutate are options for the treatment of actinic keratosis but does not provide a preference for one agent over others. The comparative evidence among the agents remains limited as most studies had a small sample size and were conducted in a single center. The results of these studies are conflicting, and clear evidence for a certain agent having a superior efficacy and safety is lacking.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Fluorouracil 5% Crm Fluorouracil Soln Imiquimod 5% 	<ul style="list-style-type: none"> Aldara® Carac® Diclofenac 3% Gel Efudex® Fluorouracil 0.5% Crm Imiquimod 3.75% Picato® Solaraze® Tolak® Zyclara®

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied